To the full analysis
Ventas stock: growth
VTRVentas reported $5.83B in revenue for fiscal 2025, up 18.5% on the prior year, up 9% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
14.9%
per year from 2006 to 2025, per share 6.3%
Earnings (Annual rate)
3.5%
per year from 2006 to 2025, per share −4.3%
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 9.0% | 5.9% | 14.9% |
| Revenue per share | 4.7% | 2.6% | 6.3% |
| Earnings | −10.6% | −5.0% | 3.5% |
| Earnings per share | −14.2% | −8.0% | −4.3% |
| Free cash flow | −0.3% | 0.0% | no data |
| Free cash flow per share | −4.2% | −3.2% | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $418.45M | $131.43M | $0 |
| 2007 | $771.79M | $282.32M | $393.44M |
| 2008 | $929.77M | $226.29M | $363.55M |
| 2009 | $931.58M | $266.5M | $408.3M |
| 2010 | $1.02B | $246.17M | $427.77M |
| 2011 | $1.76B | $364.49M | $675.13M |
| 2012 | $2.49B | $362.8M | $809.38M |
| 2013 | $2.81B | $453.51M | $1.02B |
| 2014 | $3.08B | $475.77M | $1.06B |
| 2015 | $3.29B | $417.84M | $1.28B |
| 2016 | $3.44B | $649.23M | $1.25B |
| 2017 | $3.57B | $1.36B | $1.3B |
| 2018 | $3.75B | $409.47M | $1.31B |
| 2019 | $3.87B | $433.02M | $1.28B |
| 2020 | $3.8B | $439.15M | $1.3B |
| 2021 | $3.83B | $49.01M | $858.69M |
| 2022 | $4.13B | −$47.45M | $926.34M |
| 2023 | $4.5B | −$40.97M | $935.13M |
| 2024 | $4.92B | $81.15M | $1.06B |
| 2025 | $5.83B | $251.38M | $1.28B |
Revenue by segment
How Ventas, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Senior Living Operations$4.3B73%
- Outpatient Medical And Research Portfolio$897.9M15%
- Triple Net Leased Properties$601.6M10%
The company split earlier years differently. A history would not be comparable, so only 2025 is shown.
Figures as a table
| 2025 | Share 2025 | |
|---|---|---|
| Senior Living Operations | $4.28B | 73.3% |
| Outpatient Medical And Research Portfolio | $897.9M | 15.4% |
| Triple Net Leased Properties | $601.58M | 10.3% |
| Total revenue | $5.83B | 100% |
Revenue by region
Where Ventas, Inc. generates its revenue.
- United States89%
- Canada9%
- United Kingdom1%
Figures as a table
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $3.24B | $3.36B | $3.52B | $3.58B | $3.38B | $3.36B | $3.65B | $4B | $4.37B | $5.21B | 89.3% |
| Canada | $174.83M | $186.05M | $192.35M | $266.95M | $389.21M | $434.86M | $449.09M | $464.77M | $526.58M | $552.92M | 9.5% |
| United Kingdom | $26.34M | $26.42M | no data | no data | $24.8M | $29.95M | $27.78M | $28.88M | $30.74M | $71.23M | 1.2% |
| Total revenue | $3.44B | $3.57B | $3.75B | $3.87B | $3.8B | $3.83B | $4.13B | $4.5B | $4.92B | $5.83B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.